Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2020

01-12-2020 | Endometrial Cancer | Primary research

Integrated analysis of immune-related genes in endometrial carcinoma

Authors: Yiru Wang, Yunduo Liu, Yue Guan, Hao Li, Yuan Liu, Mengjun Zhang, Ping Cui, Dan Kong, Xiuwei Chen, Hang Yin

Published in: Cancer Cell International | Issue 1/2020

Login to get access

Abstract

Background

Exploring novel and sensitive targets is urgent due to the high morbidity of endometrial cancer (EC). The purpose of our study was to explore the transcription factors and immune-related genes in EC and further identify immune-based lncRNA signature as biomarker for predicting survival prognosis.

Methods

Transcription factors, aberrantly expressed immune-related genes and immune-related lncRNAs were explored through bioinformatics analysis. Cox regression and the least absolute shrinkage and selection operator (LASSO) analysis were conducted to identify the immune and overall survival (OS) related lncRNAs. The accuracy of model was evaluated by Kaplan–Meier method and receiver operating characteristic (ROC) analysis, and the independent prognostic indicator was identified with Cox analysis. Quantitative real-time polymerase chain reaction (qRT-PCR) were conducted to detect the accuracy of our results.

Results

A network of 29 transcription factors and 17 immune-related genes was constructed. Furthermore, four immune-prognosis-related lncRNAs were screened out. Kaplan–Meier survival analysis and time-dependent ROC analysis revealed a satisfactory predictive potential of the 4-lncRNA model. Consistency was achieved among the results from the training set, testing set and entire cohort. The distributed patterns between the high- and low-risk groups could be distinguished in principal component analysis. Comparisons of the risk score and clinical factors confirmed the four-lncRNA-based signature as an independent prognostic indicator. Last, the reliability of the results was verified by qRT-PCR in 29 cases of endometrial carcinoma and in cells.

Conclusions

Overall, our study constructed a network of transcription factors and immune-related genes and explored a four immune-related lncRNA signature that could serve as a novel potential biomarker of EC.
Appendix
Available only for authorised users
Literature
1.
Byrne FL, Poon IK, Modesitt SC, Tomsig JL, Chow JD, Healy ME, Baker WD, Atkins KA, Lancaster JM, Marchion DC, et al. Metabolic vulnerabilities in endometrial cancer. Can Res. 2014;74(20):5832–45.CrossRef
2.
Soumerai TE, Donoghue MTA, Bandlamudi C, Srinivasan P, Chang MT, Zamarin D, Cadoo KA, Grisham RN, O'Cearbhaill RE, Tew WP, et al. Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer. Clin Cancer Res. 2018;24(23):5939–47.PubMedPubMedCentralCrossRef
3.
Bruegl AS, Ring KL, Daniels M, Fellman BM, Urbauer DL, Broaddus RR. Clinical challenges associated with universal screening for lynch syndrome-associated endometrial cancer. Cancer Prev Res (Philadelphia, Pa). 2017;10(2):108–15.CrossRef
4.
Bian X, Gao J, Luo F, Rui C, Zheng T, Wang D, Wang Y, Roberts TM, Liu P, Zhao JJ, et al. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy. Oncogene. 2018;37(3):341–51.PubMedCrossRef
5.
Zhao Y, Yang Y, Trovik J, Sun K, Zhou L, Jiang P, Lau TS, Hoivik EA, Salvesen HB, Sun H, et al. A novel wnt regulatory axis in endometrioid endometrial cancer. Can Res. 2014;74(18):5103–17.CrossRef
6.
Haines K, Huang GS. Precision therapy for aggressive endometrial cancer by reactivation of protein phosphatase 2A. Can Res. 2019;79(16):4009–100.CrossRef
7.
Kim J, Piao HL, Kim BJ, Yao F, Han Z, Wang Y, Xiao Z, Siverly AN, Lawhon SE, Ton BN, et al. Long noncoding RNA MALAT1 suppresses breast cancer metastasis. Nat Genet. 2018;50(12):1705–15.PubMedPubMedCentralCrossRef
8.
Lin C, Yang L. Long noncoding RNA in cancer: wiring signaling circuitry. Trends Cell Biol. 2018;28(4):287–301.PubMedCrossRef
9.
Wu Y, Yang X, Chen Z, Tian L, Jiang G, Chen F, Li J, An P, Lu L, Luo N, et al. m(6)A-induced lncRNA RP11 triggers the dissemination of colorectal cancer cells via upregulation of Zeb1. Mol Cancer. 2019;18(1):87.PubMedPubMedCentralCrossRef
10.
Zhou M, Zhao H, Xu W, Bao S, Cheng L, Sun J. Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma. Mol Cancer. 2017;16(1):16.PubMedPubMedCentralCrossRef
11.
Xu Q, Yin H, Ao H, Leng X, Liu M, Liu Y, Ma J, Wang X. An 11-lncRNA expression could be potential prognostic biomarkers in head and neck squamous cell carcinoma. J Cell Biochem. 2019;120(10):18094–103.PubMedCrossRef
12.
Yin H, Wang X, Zhang X, Wang Y, Zeng Y, Xiong Y, Li T, Lin R, Zhou Q, Ling H, et al. Integrated analysis of long noncoding RNA associated-competing endogenous RNA as prognostic biomarkers in clear cell renal carcinoma. Cancer Sci. 2018;109(10):3336–49.PubMedPubMedCentralCrossRef
13.
Keren L, Bosse M, Marquez D, Angoshtari R, Jain S, Varma S, Yang SR, Kurian A, Van Valen D, West R, et al. A structured tumor-immune microenvironment in triple negative breast cancer revealed by multiplexed ion beam imaging. Cell. 2018;174(6):1373–1387.e1319.PubMedPubMedCentralCrossRef
14.
Ferriss JS, Williams-Brown MY. Immunotherapy: checkpoint inhibitors in lynch-associated gynecologic cancers. Curr Treat Options Oncol. 2019;20(10):75.PubMedCrossRef
15.
Marinelli O, Annibali D, Aguzzi C, Tuyaerts S, Amant F, Morelli MB, Santoni G, Amantini C, Maggi F, Nabissi M. The controversial role of PD-1 and its ligands in gynecological malignancies. Front Oncol. 2019;9:1073.PubMedPubMedCentralCrossRef
16.
Chen YG, Satpathy AT, Chang HY. Gene regulation in the immune system by long noncoding RNAs. Nat Immunol. 2017;18(9):962–72.PubMedCrossRef
17.
18.
Igarashi K, Kurosaki T, Roychoudhuri R. BACH transcription factors in innate and adaptive immunity. Nat Rev Immunol. 2017;17(7):437–50.PubMedCrossRef
19.
Zaiss DMW, Coffer PJ. Forkhead box transcription factors as context-dependent regulators of lymphocyte homeostasis. Nat Rev Immunol. 2018;18(11):703–15.PubMedCrossRef
20.
Liu T, Ortiz JA, Taing L, Meyer CA, Lee B, Zhang Y, Shin H, Wong SS, Ma J, Lei Y, et al. Cistrome: an integrative platform for transcriptional regulation studies. Genome Biol. 2011;12(8):R83.PubMedPubMedCentralCrossRef
21.
Zalocusky KA, Kan MJ, Hu Z, Dunn P, Thomson E, Wiser J, Bhattacharya S, Butte AJ. The 10,000 Immunomes project: building a resource for human immunology. Cell Rep. 2018;25(2):513–522.e513.PubMedPubMedCentralCrossRef
22.
Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–504.PubMedPubMedCentralCrossRef
23.
Wang X, Yin H, Zhang H, Hu J, Lu H, Li C, Cao M, Yan S, Cai L. NF-κB-driven improvement of EHD1 contributes to erlotinib resistance in EGFR-mutant lung cancers. Cell Death Dis. 2018;9(4):418.PubMedPubMedCentralCrossRef
24.
Yin H, Ma J, Chen L, Piao S, Zhang Y, Zhang S, Ma H, Li Y, Qu Y, Wang X, et al. MiR-99a Enhances the Radiation Sensitivity of Non-Small Cell Lung Cancer by Targeting mTOR. Cell Physiol Biochem. 2018;46(2):471–81.PubMedCrossRef
25.
O'Mara TA, Zhao M, Spurdle AB. Meta-analysis of gene expression studies in endometrial cancer identifies gene expression profiles associated with aggressive disease and patient outcome. Sci Rep. 2016;6:36677.PubMedPubMedCentralCrossRef
26.
Wang Y, Ren F, Chen P, Liu S, Song Z, Ma X. Identification of a six-gene signature with prognostic value for patients with endometrial carcinoma. Cancer Med. 2018;7(11):5632–42.PubMedPubMedCentralCrossRef
27.
Liu L, Lin J, He H. Identification of potential crucial genes associated with the pathogenesis and prognosis of endometrial cancer. Front Genet. 2019;10:373.PubMedPubMedCentralCrossRef
28.
Wang ZH, Zhang YZ, Wang YS, Ma XX. Identification of novel cell glycolysis related gene signature predicting survival in patients with endometrial cancer. Cancer Cell Int. 2019;19:296.PubMedPubMedCentralCrossRef
29.
Brooks RA, Fleming GF, Lastra RR, Lee NK, Moroney JW, Son CH, Tatebe K, Veneris JL. Current recommendations and recent progress in endometrial cancer. CA a Cancer J Clin. 2019;69(4):258–79.
30.
Chen X, Dai M, Zhu H, Li J, Huang Z, Liu X, Huang Y, Chen J, Dai S. Evaluation on the diagnostic and prognostic values of long non-coding RNA BLACAT1 in common types of human cancer. Mol Cancer. 2017;16(1):160.PubMedPubMedCentralCrossRef
31.
Hosseini ES, Meryet-Figuiere M, Sabzalipoor H, Kashani HH, Nikzad H, Asemi Z. Dysregulated expression of long noncoding RNAs in gynecologic cancers. Mol Cancer. 2017;16(1):107.PubMedPubMedCentralCrossRef
32.
Pan X, Li D, Huo J, Kong F, Yang H, Ma X. LINC01016 promotes the malignant phenotype of endometrial cancer cells by regulating the miR-302a-3p/miR-3130-3p/NFYA/SATB1 axis. Cell Death Dis. 2018;9(3):303.PubMedPubMedCentralCrossRef
33.
34.
Yang J, Hu L. Immunomodulators targeting the PD-1/PD-L1 protein-protein interaction: from antibodies to small molecules. Med Res Rev. 2018;39:265–301.PubMedCrossRef
35.
36.
37.
Gao W, Qi CQ, Feng MG, Yang P, Liu L, Sun SH. SOX2-induced upregulation of lncRNA LINC01561 promotes non-small-cell lung carcinoma progression by sponging miR-760 to modulate SHCBP1 expression. J Cell Physiol. 2020;235(10):6684–96.PubMedCrossRef
38.
Zemmour D, Pratama A, Loughhead SM, Mathis D, Benoist C. Flicr, a long noncoding RNA, modulates Foxp3 expression and autoimmunity. Proc Natl Acad Sci USA. 2017;114(17):E3472–e34803480.PubMedCrossRefPubMedCentral
39.
Bianco C, Thompson L, Mohr I. Repression of eEF2K transcription by NF-κB tunes translation elongation to inflammation and dsDNA-sensing. Proc Natl Acad Sci USA. 2019;116(45):22583–90.PubMedCrossRefPubMedCentral
40.
Delpoux A, Michelini RH, Verma S, Lai CY, Omilusik KD, Utzschneider DT, Redwood AJ, Goldrath AW, Benedict CA, Hedrick SM. Continuous activity of Foxo1 is required to prevent anergy and maintain the memory state of CD8(+) T cells. J Exp Med. 2018;215(2):575–94.PubMedPubMedCentralCrossRef
41.
42.
Kingwell K. Anticancer drugs: translational target for checkpoint inhibitors. Nat Rev Drug Discov. 2018;17(12):863.PubMedCrossRef
43.
Dong P, Xiong Y, Yue J, Hanley SJB, Kobayashi N, Todo Y, Watari H. Exploring lncRNA-mediated regulatory networks in endometrial cancer cells and the tumor microenvironment: advances and challenges. Cancers. 2019;11(2):234.PubMedCentralCrossRef
44.
Serviss JT, Andrews N, Van den Eynden J, Richter FC, Houtman M, Vesterlund M, Schwarzmueller L, Johnsson P, Larsson E, Grander D, et al. An antisense RNA capable of modulating the expression of the tumor suppressor microRNA-34a. Cell Death Dis. 2018;9(7):736.PubMedPubMedCentralCrossRef
Metadata
Title
Integrated analysis of immune-related genes in endometrial carcinoma
Authors
Yiru Wang
Yunduo Liu
Yue Guan
Hao Li
Yuan Liu
Mengjun Zhang
Ping Cui
Dan Kong
Xiuwei Chen
Hang Yin
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2020
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-020-01572-6

Other articles of this Issue 1/2020

Cancer Cell International 1/2020 Go to the issue

Primary research

Circ_LDLR promoted the development of papillary thyroid carcinoma via regulating miR-195-5p/LIPH axis

Primary research

Long noncoding RNA HOTAIR promotes breast cancer development by targeting ZEB1 via sponging miR-601

Review

Long noncoding RNAs as potential biomarkers in retinoblastoma: a systematic review and meta-analysis

Review

Emerging roles of RNA methylation in gastrointestinal cancers

Primary research

Overexpression of FES might inhibit cell proliferation, migration, and invasion of osteosarcoma cells

Primary research

Association between TERT gene polymorphisms and acute myeloid leukemia susceptibility in a Chinese population: a case–control study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits